Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "Rho GTPase activating protein 17 pseudogene" (ENSG00000258387) is a pseudogene, a genomic DNA sequence similar to a known gene but non-functional due to mutations or missing regulatory elements. Its sequence resembles Rho GTPase activating protein 17 (ARHGAP17), which is a protein-coding gene involved in regulating small GTPases (notably CDC42), maintaining cell polarity, and tight junction dynamics[1][6]. However, as a pseudogene, ENSG00000258387 does not encode a functional protein, is not involved in any well-characterized cellular pathway, and is not considered a therapeutic target. There are no known aliases, drugs, disease associations, or direct biological functions or classifications for this pseudogene. Most relevant context: Therapeutic research, drug targeting, and molecular pathway studies should focus on the functional ARHGAP17 (Rho GTPase activating protein 17) gene and its encoded protein, not this pseudogene. Pseudogenes generally serve as genomic markers or may have regulatory RNA functions in rare cases, but are not considered drug targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rho GTPase activating protein 17 pseudogene.